Trial Profile
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Solid tumours
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer; Pfizer Global Research and Development
- 10 Jan 2012 Actual patient number changed from 310 to 313 as reported by ClinicalTrials.gov.
- 16 Dec 2011 Actual patient number is 310 as reported by ClinicalTrials.gov.
- 16 Dec 2011 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.